Extracellular vesicles in neurodegenerative disease-pathogenesis to biomarkers

Nature Reviews Neurology

Volumn 12, Issue 6, 2016, Pages 346-357

  Thompson, Alexander G ^a   Gray, Elizabeth ^a   Heman Ackah, Sabrina M ^a   Mäger, Imre ^a   Talbot, Kevin ^a   El Andaloussi, Samir ^a,b   Wood, Matthew J ^a   Turner, Martin R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ARRESTIN DOMAIN CONTAINING PROTEIN 1; BIOLOGICAL MARKER; CELL PROTEIN; LEUCINE RICH REPEAT KINASE 2; MEMBRANE PROTEIN; MICRORNA; NUCLEIC ACID; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOTIC BODY; CELL COMPONENT; DEGENERATIVE DISEASE; EXOSOME; HUMAN; MEMBRANE MICROPARTICLE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL NOISE RATIO; TAUOPATHY; BLOOD; CEREBROSPINAL FLUID;

BIOMARKERS; EXTRACELLULAR VESICLES; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84968546839     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.68     Document Type: Review

References (159)

1. Poste G. Bring on the biomarkers. Nature. 469, 156-157 (2011).
2. Braak H, et al. Staging of brain pathology related to sporadic Parkinson?s disease. Neurobiol. Aging. 24, 197-211 (2003).
3. Braak H, & Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
4. Brettschneider J, et al. Stages of pTDP 43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20-38 (2013).
5. Lebouvier T, et al. Pathological lesions in colonic biopsies during Parkinson?s disease. Gut. 57, 1741-1743 (2008).
6. Blennow K, & Zetterberg H. Understanding biomarkers of neurodegeneration: ultrasensitive detection techniques pave the way for mechanistic understanding. Nat. Med. 21, 217-219 (2015).
7. Yanez Mo M, et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles. 4, 27066 (2015).
8. de Jong O. G, et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. J. Extracell. Vesicles http://dx.doi.org/10.3402/jev.v1i0.18396 (2012).
9. Eldh M, et al. Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS ONE 5, e15353 (2010).
10. Alexander M, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat. Commun. 6, 7321 (2015).
11. Guescini M, Genedani S, Stocchi V, & Agnati L. F. Astrocytes and glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna) 117, 1-4 (2010).
12. Chiasserini D, et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. J. Proteomics. 106, 191-204 (2014).
13. Shi M, et al. Plasma exosomal α synuclein is likely CNS-derived and increased in Parkinson?s disease. Acta Neuropathol. 128, 639-650 (2014).
14. Cheng L, Sharples R. A, Scicluna B. J, & Hill A. F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J. Extracell. Vesicles http://dx.doi.org/10.3402/jev.v3.23743 (2014).
15. Faure J, et al. Exosomes are released by cultured cortical neurones. Mol. Cell. Neurosci. 31, 642-648 (2006).
16. Colombo M, Raposo G, & Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255-289 (2014).
17. Kalra H, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 10, e1001450 (2012).
18. van Niel G, et al. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev. Cell. 21, 708-721 (2011).
19. Perez-Hernandez D, et al. The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes. J. Biol. Chem. 288, 11649-11661 (2013).
20. Carayon K, et al. Proteolipidic composition of exosomes changes during reticulocyte maturation. J. Biol. Chem. 286, 34426-34439 (2011).
21. Heijnen H. F, Schiel A. E, Fijnheer R, Geuze H. J, & Sixma J. J. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood. 94, 3791-3799 (1999).
22. Raposo G, & Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200, 373-383 (2013).
23. Lotvall J, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the InterNational Society for Extracellular Vesicles. J. Extracell. Vesicles. 3, 26913 (2014).
24. Muralidharan-Chari V, et al. ARF6 regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr. Biol. 19, 1875-1885 (2009).
25. Nabhan J. F, Hu R, Oh R. S, Cohen S. N, & Lu Q. Formation and release of arrestin domain-containing protein 1 mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. Proc. Natl Acad. Sci. USA. 109, 4146-4151 (2012).
26. Muralidharan-Chari V, Clancy J. W, Sedgwick A, & D?Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 123, 1603-1611 (2010).
27. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35, 495-516 (2007).
28. Bellingham S. A, Coleman B. M, & Hill A. F. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res. 40, 10937-10949 (2012).
29. Huang X, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 14, 319 (2013).
30. Balaj L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011).
31. Thakur B. K, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766-769 (2014).
32. Keerthikumar S, et al. ExoCarta: a Web-based compendium of exosomal cargo. J. Mol. Biol. 428, 688-692 (2016).
33. Nordin J. Z, et al. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine. 11, 879-883 (2015).
34. Montecalvo A, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 119, 756-766 (2012).
35. Lee Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 487, 443-448 (2012).
36. Kramer-Albers E. M, et al. Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: trophic support for axons? Proteomics Clin. Appl. 1, 1446-1461 (2007).
37. Antonucci F, et al. Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism. EMBO J. 31, 1231-1240 (2012).
38. Pan B. T, & Johnstone R. M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967-977 (1983).
39. Budnik V, Ruiz-Canada C, & Wendler F. Extracellular vesicles round off communication in the nervous system. Nat. Rev. Neurosci. 17, 160-172 (2016).
40. Zhuang X, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 19, 1769-1779 (2011).
41. Alvarez-Erviti L, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341-345 (2011).
42. Cooper J. M, et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 29, 1476-1485 (2014).
43. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer?s disease patients. Acta Neuropathol. 91, 6-14 (1996).
44. Ridder K, et al. Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol. 12, e1001874 (2014).
45. Zakharov A, Papaiconomou C, Djenic J, Midha R, & Johnston M. Lymphatic cerebrospinal fluid absorption pathways in neonatal sheep revealed by subarachnoid injection of Microfil. Neuropathol. Appl. Neurobiol. 29, 563-573 (2003).
46. Weed L. The pathways of escape from the subarachnoid spaces with particular reference to the arachnoid villi. J. Med. Res. 31, 51-59 (1914).
47. Glimcher S. A, Holman D. W, Lubow M, & Grzybowski D. M. Ex vivo model of cerebrospinal fluid outflow across human arachnoid granulations. Invest. Ophthalmol. Vis. Sci. 49, 4721-4728 (2008).
48. Louveau A, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 523, 337-341 (2015).
49. Haqqani A. S, et al. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids Barriers CNS. 10, 4 (2013).
50. Looze C, et al. Proteomic profiling of human plasma exosomes identifies PPAR? as an exosome-Associated protein. Biochem. Biophys. Res. Commun. 378, 433-438 (2009).
51. Tomlinson P. R, et al. Identification of distinct circulating exosomes in Parkinson?s disease. Ann. Clin. Transl. Neurol. 2, 353-361 (2015).
52. de Menezes-Neto A, et al. Size-exclusion chromatography as a stand-Alone methodology identifies novel markers in mass spectrometry analyses of plasma-derived vesicles from healthy individuals. J. Extracell. Vesicles. 4, 27378 (2015).
53. Mellinghoff I. K, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
54. Ilieva H, Polymenidou M, & Cleveland D. W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187, 761-772 (2009).
55. McNaught K. S, Belizaire R, Isacson O, Jenner P, & Olanow C. W. Altered proteasomal function in sporadic Parkinson?s disease. Exp. Neurol. 179, 38-46 (2003).
56. Winklhofer K. F, & Haass C. Mitochondrial dysfunction in Parkinson?s disease. Biochim. Biophys. Acta 1802, 29-44 (2010).
57. Vanden Broeck L, Callaerts P, & Dermaut B. TDP 43 mediated neurodegeneration: towards a loss of function hypothesis? Trends Mol. Med. 20, 66-71 (2014).
58. Terwel D, Dewachter I, & Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer?s disease. Neuromolecular Med. 2, 151-165 (2002).
59. Katayama T, et al. Induction of neuronal death by ER stress in Alzheimer?s disease. J. Chem. Neuroanat. 28, 67-78 (2004).
60. Leitman J, Ulrich Hartl F, & Lederkremer G. Z. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nat. Commun. 4, 2753 (2013).
61. Joshi P, et al. Microglia convert aggregated amyloid β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 21, 582-593 (2014).
62. Yuyama K, et al. A potential function for neuronal exosomes: sequestering intracerebral amyloid-β peptide. FEBS Lett. 589, 84-88 (2015).
63. Prusiner S. B. Novel proteinaceous infectious particles cause scrapie. Science. 216, 136-144 (1982).
64. Polymenidou M, & Cleveland D. W. The seeds of neurodegeneration: prion-like spreading in ALS. Cell. 147, 498-508 (2011).
65. Wadia J. S, Schaller M, Williamson R. A, & Dowdy S. F. Pathologic prion protein infects cells by lipid-raft dependent macropinocytosis. PLoS ONE 3, e3314 (2008).
66. Gousset K, et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 11, 328-336 (2009).
67. Vella L. J, et al. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J. Pathol. 211, 582-590 (2007).
68. Schatzl H. M, et al. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J. Virol. 71, 8821-8831 (1997).
69. Fevrier B, et al. Cells release prions in association with exosomes. Proc. Natl Acad. Sci. USA. 101, 9683-9688 (2004).
70. Alais S, et al. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biol. Cell. 100, 603-615 (2008).
71. Gross J. C, Chaudhary V, Bartscherer K, & Boutros M. Active Wnt proteins are secreted on exosomes. Nat. Cell Biol. 14, 1036-1045 (2012).
72. Arellano-Anaya Z. E, et al. Prion strains are differentially released through the exosomal pathway. Cell. Mol. Life Sci. 72, 1185-1196 (2015).
73. Guo B. B, Bellingham S. A, & Hill A. F. Stimulating the release of exosomes increases the intercellular transfer of prions. J. Biol. Chem. 291, 5128-5137 (2016).
74. Vella L. J, Greenwood D. L, Cappai R, Scheerlinck J. P, & Hill A. F. Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. Vet. Immunol. Immunopathol. 124, 385-393 (2008).
75. Lee V. M, Balin B. J, Otvos L. Jr & Trojanowski J. Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 251, 675-678 (1991).
76. Yamaguchi H, et al. Alzheimer type dementia: diffuse type of senile plaques demonstrated by beta protein immunostaining. Prog. Clin. Biol. Res. 317, 467-474 (1989).
77. Harper J. D, & Lansbury P. T. Jr. Models of amyloid seeding in Alzheimer?s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407 (1997).
78. Baker H. F, Ridley R. M, Duchen L. W, Crow T. J, & Bruton C. J. Induction of β(A4)-Amyloid in primates by injection of Alzheimer?s disease brain homogenate. Mol. Neurobiol. 8, 25-39 (1994).
79. Kane M. D, et al. Evidence for seeding of β amyloid by intracerebral infusion of Alzheimer brain extracts in β amyloid precursor protein-Transgenic mice. J. Neurosci. 20, 3606-3611 (2000).
80. Rajendran L, et al. Alzheimer?s disease β amyloid peptides are released in association with exosomes. Proc. Natl Acad. Sci. USA. 103, 11172-11177 (2006).
81. Yuyama K, Sun H, Mitsutake S, & Igarashi Y. Sphingolipid-modulated exosome secretion promotes clearance of amyloid β by microglia. J. Biol. Chem. 287, 10977-10989 (2012).
82. An K, et al. Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo. Mol. Brain. 6, 47 (2013).
83. Dinkins M. B, Dasgupta S, Wang G, Zhu G, & Bieberich E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer?s disease. Neurobiol. Aging. 35, 1792-1800 (2014).
84. Yuyama K, et al. Decreased amyloid β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice. J. Biol. Chem. 289, 24488-24498 (2014).
85. Josephs K. A. Frontotemporal dementia and related disorders: deciphering the enigma. Ann. Neurol. 64, 4-14 (2008).
86. Santa-Maria I, et al. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J. Biol. Chem. 287, 20522-20533 (2012).
87. Saman S, et al. Exosome-Associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287, 3842-3849 (2012).
88. Asai H, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584-1593 (2015).
89. McCann H, Stevens C. H, Cartwright H, & Halliday G. M. α synucleinopathy phenotypes. Parkinsonism Relat. Disord. 20, S62-S67 (2014).
90. Spillantini M. G, et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson?s disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208 (1998).
91. Irizarry M. C, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson?s disease and cortical Lewy body disease contain α synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334-337 (1998).
92. Desplats P, et al. Inclusion formation and neuronal cell death through neuron-To neuron transmission of α synuclein. Proc. Natl Acad. Sci. USA. 106, 13010-13015 (2009).
93. Lee H. J, Patel S, & Lee S. J. Intravesicular localization and exocytosis of α synuclein and its aggregates. J. Neurosci. 25, 6016-6024 (2005).
94. Lee H. J, Suk J. E, Bae E. J, & Lee S. J. Clearance and deposition of extracellular α synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 372, 423-428 (2008).
95. Kordower J. H, Chu Y, Hauser R. A, Freeman T. B, & Olanow C. W. Lewy body-like pathology in long-Term embryonic nigral transplants in Parkinson?s disease. Nat. Med. 14, 504-506 (2008).
96. Danzer K. M, et al. Exosomal cell to cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42 (2012).
97. Grey M, et al. Acceleration of α synuclein aggregation by exosomes. J. Biol. Chem. 290, 2969-2982 (2015).
98. Emmanouilidou E, et al. Cell-produced α synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838-6851 (2010).
99. Alvarez-Erviti L, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 42, 360-367 (2011).
100. Martin I, Kim J. W, Dawson V. L, & Dawson T. M. LRRK2 pathobiology in Parkinson?s disease. J. Neurochem. 131, 554-565 (2014).
101. Fraser K. B, et al. LRRK2 secretion in exosomes is regulated by 14 3 3. Hum. Mol. Genet. 22, 4988-5000 (2013).
102. Arai T, et al. TDP 43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602-611 (2006).
103. Neumann M, et al. Ubiquitinated TDP 43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 314, 130-133 (2006).
104. Rutherford N. J, et al. Novel mutations in TARDBP (TDP 43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 4, e1000193 (2008).
105. Guo W, et al. An ALS-Associated mutation affecting TDP 43 enhances protein aggregation, fibril formation and neurotoxicity. Nat. Struct. Mol. Biol. 18, 822-830 (2011).
106. Yang C, et al. The C terminal TDP 43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS ONE 5, e15878 (2010).
107. Mackenzie I. R, Frick P, & Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol. 127, 347-357 (2014).
108. Shibata N, et al. Intense superoxide dismutase 1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J. Neuropathol. Exp. Neurol. 55, 481-490 (1996).
109. Deng H. X, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 67, 739-748 (2010).
110. Nonaka T, et al. Prion-like properties of pathological TDP 43 aggregates from diseased brains. Cell Rep. 4, 124-134 (2013).
111. Chia R, et al. Superoxide dismutase 1 and tgSOD1G93A mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS ONE 5, e10627 (2010).
112. Munch C, O?Brien J, & Bertolotti A. Prion-like propagation of mutant superoxide dismutase 1 misfolding in neuronal cells. Proc. Natl Acad. Sci. USA. 108, 3548-3553 (2011).
113. Feneberg E, et al. Limited role of free TDP 43 as a diagnostic tool in neurodegenerative diseases. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 351-356 (2014).
114. Feiler M. S, et al. TDP 43 is intercellularly transmitted across axon terminals. J. Cell Biol. 211, 897-911 (2015).
115. Gomes C, Keller S, Altevogt P, & Costa J. Evidence for secretion of Cu, Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neurosci. Lett. 428, 43-46 (2007).
116. Grad L. I, et al. Intercellular propagated misfolding of wild-Type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc. Natl Acad. Sci. USA. 111, 3620-3625 (2014).
117. Peinado H, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891 (2012).
118. Silva J, et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer. 51, 409-418 (2012).
119. Kwak E. L, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
120. Stuendl A, et al. Induction of α synuclein aggregate formation by CSF exosomes from patients with Parkinson?s disease and dementia with Lewy bodies. Brain. 139, 481-494 (2016).
121. Goetzl E. J, et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology. 85, 40-47 (2015).
122. Fiandaca M. S, et al. Identification of preclinical Alzheimer?s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement. 11, 600-607.e1 (2015).
123. Foulds P. G, et al. Plasma phosphorylated-TDP 43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol. 118, 647-658 (2009).
124. Kasai T, et al. Increased TDP 43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 117, 55-62 (2009).
125. Zandberga E, et al. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer. 52, 356-369 (2013).
126. Tan L, Yu J. T, & Tan L. Causes and consequences of microRNA dysregulation in neurodegenerative diseases. Mol. Neurobiol. 51, 1249-1262 (2015).
127. Schipper H. M, Maes O. C, Chertkow H. M, & Wang E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul. Syst. Bio. 1, 263-274 (2007).
128. Cogswell J. P, et al. Identification of miRNA changes in Alzheimer?s disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 14, 27-41 (2008).
129. Geekiyanage H, Jicha G. A, Nelson P. T, & Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer?s disease. Exp. Neurol. 235, 491-496 (2012).
130. Kiko T, et al. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer?s disease. J. Alzheimers Dis. 39, 253-259 (2014).
131. Freischmidt A, et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 137, 2938-2950 (2014).
132. Bhatnagar S, et al. Increased microRNA 34c abundance in Alzheimer?s disease circulating blood plasma. Front. Mol. Neurosci. 7, 2 (2014).
133. Shehadeh L, Mitsi G, Adi N, Bishopric N, & Papapetropoulos S. Expression of Lewy body protein septin 4 in postmortem brain of Parkinson?s disease and control subjects. Mov. Disord. 24, 204-210 (2009).
134. Filatova E. V, Alieva A, Shadrina M. I, & Slominsky P. A. MicroRNAs: possible role in pathogenesis of Parkinson?s disease. Biochemistry (Mosc.) 77, 813-819 (2012).
135. Chandrasekaran S, & Bonchev D. A network view on Parkinson?s disease. Comput. Struct. Biotechnol. J. 7, e201304004 (2013).
136. Margis R, Margis R, & Rieder C. R. Identification of blood microRNAs associated to Parkinson?s disease. J. Biotechnol. 152, 96-101 (2011).
137. Martins M, et al. Convergence of miRNA expression profiling, α synuclein interacton and GWAS in Parkinson?s disease. PLoS ONE 6, e25443 (2011).
138. Burgos K, et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer?s and Parkinson?s diseases correlate with disease status and features of pathology. PLoS ONE 9, e94839 (2014).
139. Serafin A, et al. Overexpression of Blood MicroRNAs 103a, 30b, and 29a in L Dopa-Treated Patients with PD. Neurology. 84, 645-653 (2015).
140. Kawahara Y, & Mieda-Sato A. TDP 43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl Acad. Sci. USA. 109, 3347-3352 (2012).
141. Freischmidt A, Muller K, Ludolph A. C, & Weishaupt J. H. Systemic dysregulation of TDP 43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 1, 42 (2013).
142. Freischmidt A, et al. Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 36, 2660.e15-2660.e20 (2015).
143. Liu C. G, Song J, Zhang Y. Q, & Wang P. C. MicroRNA 193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA 193b is a biomarker of Alzheimer?s disease. Mol. Med. Rep. 10, 2395-2400 (2014).
144. Lugli G, et al. Plasma exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers. PLoS ONE 10, e0139233 (2015).
145. Cheng L, et al. Prognostic serum miRNA biomarkers associated with Alzheimer?s disease shows concordance with neuropsychological and neuroimaging assessment. Mol. Psychiatry. 20, 1188-1196 (2015).
146. Gui Y. X, Liu H, Zhang L. S, Lv W, & Hu X. Y. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 6, 37043-37053 (2015).
147. Thery C, Amigorena S, Raposo G, & Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Chapter. 3, 3.22 (2006).
148. Arroyo J. D, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA. 108, 5003-5008 (2011).
149. Kalra H, et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics. 13, 3354-3364 (2013).
150. Lobb R. J, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J. Extracell. Vesicles. 4, 27031 (2015).
151. Witwer K. W, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles. 2, 20360 (2013).
152. Hsu C, et al. Regulation of exosome secretion by Rab35 and its GTPase-Activating proteins TBC1D10A C. J. Cell Biol. 189, 223-232 (2010).
153. Ostrowski M, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19-30 (2010).
154. Morelli A. E, et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood. 104, 3257-3266 (2004).
155. Mulcahy L. A, Pink R. C, & Carter D. R. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles. 3, 24641 (2014).
156. Gitler A. D, et al. The Parkinson?s disease protein α synuclein disrupts cellular Rab homeostasis. Proc. Natl Acad. Sci. USA. 105, 145-150 (2008).
157. Topp J. D, Gray N. W, Gerard R. D, & Horazdovsky B. F. Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor. J. Biol. Chem. 279, 24612-24623 (2004).
158. Nishimura A. L, et al. A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 20q13. J. Med. Genet. 41, 315-320 (2004).
159. Wang Y, Cui J, Sun X, & Zhang Y. Tunneling-nanotube development in astrocytes depends on p53 activation. Cell Death Differ. 18, 732-742 (2011).